nodes	percent_of_prediction	percent_of_DWPC	metapath
Abiraterone—ORM1—Vandetanib—thyroid cancer	0.203	0.253	CbGbCtD
Abiraterone—ABCC1—Vandetanib—thyroid cancer	0.185	0.231	CbGbCtD
Abiraterone—ABCC1—Epirubicin—thyroid cancer	0.127	0.159	CbGbCtD
Abiraterone—ALB—Vandetanib—thyroid cancer	0.0852	0.107	CbGbCtD
Abiraterone—ABCC1—Doxorubicin—thyroid cancer	0.0676	0.0845	CbGbCtD
Abiraterone—CYP2C8—Sorafenib—thyroid cancer	0.0397	0.0496	CbGbCtD
Abiraterone—CYP3A4—Vandetanib—thyroid cancer	0.0267	0.0334	CbGbCtD
Abiraterone—CYP2D6—Sorafenib—thyroid cancer	0.0253	0.0316	CbGbCtD
Abiraterone—CYP3A4—Sorafenib—thyroid cancer	0.0161	0.0201	CbGbCtD
Abiraterone—CYP2D6—Doxorubicin—thyroid cancer	0.0154	0.0192	CbGbCtD
Abiraterone—Potassium low—Vandetanib—thyroid cancer	0.0139	0.0768	CcSEcCtD
Abiraterone—CYP3A4—Doxorubicin—thyroid cancer	0.00977	0.0122	CbGbCtD
Abiraterone—Potassium low—Sorafenib—thyroid cancer	0.00939	0.0518	CcSEcCtD
Abiraterone—Cardio-respiratory arrest—Vandetanib—thyroid cancer	0.00817	0.0451	CcSEcCtD
Abiraterone—Blood potassium decreased—Vandetanib—thyroid cancer	0.00768	0.0423	CcSEcCtD
Abiraterone—Sudden death—Vandetanib—thyroid cancer	0.0057	0.0315	CcSEcCtD
Abiraterone—Blood potassium decreased—Sorafenib—thyroid cancer	0.00518	0.0286	CcSEcCtD
Abiraterone—Lymphopenia—Sorafenib—thyroid cancer	0.00385	0.0212	CcSEcCtD
Abiraterone—Hypophosphataemia—Sorafenib—thyroid cancer	0.00339	0.0187	CcSEcCtD
Abiraterone—Myocardial ischaemia—Sorafenib—thyroid cancer	0.00245	0.0135	CcSEcCtD
Abiraterone—Cardiac failure—Vandetanib—thyroid cancer	0.00217	0.012	CcSEcCtD
Abiraterone—Hypokalaemia—Vandetanib—thyroid cancer	0.00193	0.0106	CcSEcCtD
Abiraterone—Nasopharyngitis—Vandetanib—thyroid cancer	0.00189	0.0104	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00187	0.0103	CcSEcCtD
Abiraterone—SULT2A1—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00174	0.0929	CbGpPWpGaD
Abiraterone—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.0017	0.00939	CcSEcCtD
Abiraterone—Pollakiuria—Vandetanib—thyroid cancer	0.00169	0.00933	CcSEcCtD
Abiraterone—Hyperglycaemia—Vandetanib—thyroid cancer	0.00165	0.00911	CcSEcCtD
Abiraterone—Pneumonia—Vandetanib—thyroid cancer	0.00164	0.00906	CcSEcCtD
Abiraterone—Infestation—Vandetanib—thyroid cancer	0.00163	0.009	CcSEcCtD
Abiraterone—Infestation NOS—Vandetanib—thyroid cancer	0.00163	0.009	CcSEcCtD
Abiraterone—Urinary tract infection—Vandetanib—thyroid cancer	0.00159	0.00875	CcSEcCtD
Abiraterone—Haematuria—Vandetanib—thyroid cancer	0.00156	0.00858	CcSEcCtD
Abiraterone—Cardiac failure—Sorafenib—thyroid cancer	0.00146	0.00808	CcSEcCtD
Abiraterone—Urinary tract disorder—Vandetanib—thyroid cancer	0.00145	0.00798	CcSEcCtD
Abiraterone—Urethral disorder—Vandetanib—thyroid cancer	0.00144	0.00792	CcSEcCtD
Abiraterone—Lymphopenia—Epirubicin—thyroid cancer	0.00142	0.00784	CcSEcCtD
Abiraterone—Hypernatraemia—Epirubicin—thyroid cancer	0.00138	0.00763	CcSEcCtD
Abiraterone—Cardiac disorder—Vandetanib—thyroid cancer	0.00136	0.0075	CcSEcCtD
Abiraterone—Angiopathy—Vandetanib—thyroid cancer	0.00133	0.00733	CcSEcCtD
Abiraterone—Mediastinal disorder—Vandetanib—thyroid cancer	0.00132	0.00728	CcSEcCtD
Abiraterone—Lymphopenia—Doxorubicin—thyroid cancer	0.00132	0.00726	CcSEcCtD
Abiraterone—Arrhythmia—Vandetanib—thyroid cancer	0.00131	0.00722	CcSEcCtD
Abiraterone—Hypokalaemia—Sorafenib—thyroid cancer	0.0013	0.00717	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00129	0.0071	CcSEcCtD
Abiraterone—Mental disorder—Vandetanib—thyroid cancer	0.00128	0.00708	CcSEcCtD
Abiraterone—Hypernatraemia—Doxorubicin—thyroid cancer	0.00128	0.00706	CcSEcCtD
Abiraterone—Nasopharyngitis—Sorafenib—thyroid cancer	0.00128	0.00705	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00126	0.00695	CcSEcCtD
Abiraterone—Hypophosphataemia—Epirubicin—thyroid cancer	0.00125	0.0069	CcSEcCtD
Abiraterone—Hypophosphataemia—Doxorubicin—thyroid cancer	0.00116	0.00639	CcSEcCtD
Abiraterone—SULT2A1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00115	0.0612	CbGpPWpGaD
Abiraterone—Cough—Vandetanib—thyroid cancer	0.00111	0.00614	CcSEcCtD
Abiraterone—Pneumonia—Sorafenib—thyroid cancer	0.00111	0.00611	CcSEcCtD
Abiraterone—Hypertension—Vandetanib—thyroid cancer	0.0011	0.00607	CcSEcCtD
Abiraterone—Infestation NOS—Sorafenib—thyroid cancer	0.0011	0.00607	CcSEcCtD
Abiraterone—Infestation—Sorafenib—thyroid cancer	0.0011	0.00607	CcSEcCtD
Abiraterone—Chest pain—Vandetanib—thyroid cancer	0.00109	0.00599	CcSEcCtD
Abiraterone—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00109	0.00599	CcSEcCtD
Abiraterone—Myocardial infarction—Sorafenib—thyroid cancer	0.00108	0.00595	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00108	0.00595	CcSEcCtD
Abiraterone—Oedema—Vandetanib—thyroid cancer	0.00104	0.00574	CcSEcCtD
Abiraterone—Infection—Vandetanib—thyroid cancer	0.00103	0.0057	CcSEcCtD
Abiraterone—SULT2A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00101	0.054	CbGpPWpGaD
Abiraterone—Skin disorder—Vandetanib—thyroid cancer	0.00101	0.00558	CcSEcCtD
Abiraterone—Urinary tract disorder—Sorafenib—thyroid cancer	0.000976	0.00538	CcSEcCtD
Abiraterone—Connective tissue disorder—Sorafenib—thyroid cancer	0.000971	0.00536	CcSEcCtD
Abiraterone—Urethral disorder—Sorafenib—thyroid cancer	0.000969	0.00534	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000948	0.00523	CcSEcCtD
Abiraterone—Insomnia—Vandetanib—thyroid cancer	0.000942	0.00519	CcSEcCtD
Abiraterone—Dyspnoea—Vandetanib—thyroid cancer	0.000928	0.00512	CcSEcCtD
Abiraterone—Cardiac disorder—Sorafenib—thyroid cancer	0.000917	0.00506	CcSEcCtD
Abiraterone—Dyspepsia—Vandetanib—thyroid cancer	0.000916	0.00505	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000899	0.00496	CcSEcCtD
Abiraterone—Fatigue—Vandetanib—thyroid cancer	0.000898	0.00495	CcSEcCtD
Abiraterone—Angiopathy—Sorafenib—thyroid cancer	0.000897	0.00495	CcSEcCtD
Abiraterone—Mediastinal disorder—Sorafenib—thyroid cancer	0.000891	0.00491	CcSEcCtD
Abiraterone—Constipation—Vandetanib—thyroid cancer	0.00089	0.00491	CcSEcCtD
Abiraterone—Arrhythmia—Sorafenib—thyroid cancer	0.000883	0.00487	CcSEcCtD
Abiraterone—Mental disorder—Sorafenib—thyroid cancer	0.000866	0.00478	CcSEcCtD
Abiraterone—Body temperature increased—Vandetanib—thyroid cancer	0.000823	0.00454	CcSEcCtD
Abiraterone—Anaemia—Sorafenib—thyroid cancer	0.000795	0.00439	CcSEcCtD
Abiraterone—CYP17A1—Endogenous sterols—RXRA—thyroid cancer	0.000794	0.0423	CbGpPWpGaD
Abiraterone—Nocturia—Epirubicin—thyroid cancer	0.000784	0.00433	CcSEcCtD
Abiraterone—Cough—Sorafenib—thyroid cancer	0.000751	0.00414	CcSEcCtD
Abiraterone—Asthenia—Vandetanib—thyroid cancer	0.000747	0.00412	CcSEcCtD
Abiraterone—Hypertension—Sorafenib—thyroid cancer	0.000743	0.0041	CcSEcCtD
Abiraterone—Myalgia—Sorafenib—thyroid cancer	0.000733	0.00404	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000728	0.00401	CcSEcCtD
Abiraterone—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000727	0.00401	CcSEcCtD
Abiraterone—Nocturia—Doxorubicin—thyroid cancer	0.000726	0.004	CcSEcCtD
Abiraterone—Diarrhoea—Vandetanib—thyroid cancer	0.000712	0.00393	CcSEcCtD
Abiraterone—ABCC1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000712	0.038	CbGpPWpGaD
Abiraterone—Infection—Sorafenib—thyroid cancer	0.000698	0.00385	CcSEcCtD
Abiraterone—Fluid retention—Epirubicin—thyroid cancer	0.000691	0.00381	CcSEcCtD
Abiraterone—Skin disorder—Sorafenib—thyroid cancer	0.000682	0.00376	CcSEcCtD
Abiraterone—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.000673	0.00371	CcSEcCtD
Abiraterone—Vomiting—Vandetanib—thyroid cancer	0.000662	0.00365	CcSEcCtD
Abiraterone—Rash—Vandetanib—thyroid cancer	0.000656	0.00362	CcSEcCtD
Abiraterone—Dermatitis—Vandetanib—thyroid cancer	0.000656	0.00362	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00064	0.00353	CcSEcCtD
Abiraterone—SULT2A1—E2F transcription factor network—CDK1—thyroid cancer	0.000639	0.0341	CbGpPWpGaD
Abiraterone—Fluid retention—Doxorubicin—thyroid cancer	0.000639	0.00352	CcSEcCtD
Abiraterone—Dyspnoea—Sorafenib—thyroid cancer	0.000626	0.00345	CcSEcCtD
Abiraterone—Dyspepsia—Sorafenib—thyroid cancer	0.000618	0.00341	CcSEcCtD
Abiraterone—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000607	0.00335	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000606	0.00334	CcSEcCtD
Abiraterone—Fatigue—Sorafenib—thyroid cancer	0.000605	0.00334	CcSEcCtD
Abiraterone—Constipation—Sorafenib—thyroid cancer	0.000601	0.00331	CcSEcCtD
Abiraterone—Hot flush—Epirubicin—thyroid cancer	0.000564	0.00311	CcSEcCtD
Abiraterone—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000562	0.0031	CcSEcCtD
Abiraterone—Menopausal symptoms—Epirubicin—thyroid cancer	0.00056	0.00309	CcSEcCtD
Abiraterone—Body temperature increased—Sorafenib—thyroid cancer	0.000555	0.00306	CcSEcCtD
Abiraterone—Cardiac failure—Epirubicin—thyroid cancer	0.000541	0.00298	CcSEcCtD
Abiraterone—CYP17A1—Metapathway biotransformation—CHST14—thyroid cancer	0.000537	0.0287	CbGpPWpGaD
Abiraterone—Hot flush—Doxorubicin—thyroid cancer	0.000522	0.00288	CcSEcCtD
Abiraterone—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000518	0.00286	CcSEcCtD
Abiraterone—Asthenia—Sorafenib—thyroid cancer	0.000504	0.00278	CcSEcCtD
Abiraterone—Cardiac failure—Doxorubicin—thyroid cancer	0.000501	0.00276	CcSEcCtD
Abiraterone—Hypokalaemia—Epirubicin—thyroid cancer	0.000481	0.00265	CcSEcCtD
Abiraterone—Diarrhoea—Sorafenib—thyroid cancer	0.00048	0.00265	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000476	0.00262	CcSEcCtD
Abiraterone—Nasopharyngitis—Epirubicin—thyroid cancer	0.000472	0.0026	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000466	0.00257	CcSEcCtD
Abiraterone—Vomiting—Sorafenib—thyroid cancer	0.000447	0.00246	CcSEcCtD
Abiraterone—Hypokalaemia—Doxorubicin—thyroid cancer	0.000445	0.00245	CcSEcCtD
Abiraterone—Rash—Sorafenib—thyroid cancer	0.000443	0.00244	CcSEcCtD
Abiraterone—Dermatitis—Sorafenib—thyroid cancer	0.000442	0.00244	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00044	0.00243	CcSEcCtD
Abiraterone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000437	0.00241	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000431	0.00238	CcSEcCtD
Abiraterone—SULT2A1—PPARA activates gene expression—RXRA—thyroid cancer	0.000428	0.0228	CbGpPWpGaD
Abiraterone—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000424	0.00234	CcSEcCtD
Abiraterone—Pollakiuria—Epirubicin—thyroid cancer	0.000422	0.00233	CcSEcCtD
Abiraterone—SULT2A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000418	0.0223	CbGpPWpGaD
Abiraterone—Hyperglycaemia—Epirubicin—thyroid cancer	0.000412	0.00227	CcSEcCtD
Abiraterone—Pneumonia—Epirubicin—thyroid cancer	0.000409	0.00226	CcSEcCtD
Abiraterone—Infestation—Epirubicin—thyroid cancer	0.000407	0.00224	CcSEcCtD
Abiraterone—Infestation NOS—Epirubicin—thyroid cancer	0.000407	0.00224	CcSEcCtD
Abiraterone—Urinary tract infection—Epirubicin—thyroid cancer	0.000396	0.00218	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000392	0.00216	CcSEcCtD
Abiraterone—Pollakiuria—Doxorubicin—thyroid cancer	0.00039	0.00215	CcSEcCtD
Abiraterone—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000389	0.0207	CbGpPWpGaD
Abiraterone—Haematuria—Epirubicin—thyroid cancer	0.000388	0.00214	CcSEcCtD
Abiraterone—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.000382	0.0204	CbGpPWpGaD
Abiraterone—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000381	0.0021	CcSEcCtD
Abiraterone—Pneumonia—Doxorubicin—thyroid cancer	0.000379	0.00209	CcSEcCtD
Abiraterone—Infestation NOS—Doxorubicin—thyroid cancer	0.000377	0.00208	CcSEcCtD
Abiraterone—Infestation—Doxorubicin—thyroid cancer	0.000377	0.00208	CcSEcCtD
Abiraterone—CYP17A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000368	0.0197	CbGpPWpGaD
Abiraterone—Urinary tract infection—Doxorubicin—thyroid cancer	0.000366	0.00202	CcSEcCtD
Abiraterone—Urinary tract disorder—Epirubicin—thyroid cancer	0.000361	0.00199	CcSEcCtD
Abiraterone—Haematuria—Doxorubicin—thyroid cancer	0.000359	0.00198	CcSEcCtD
Abiraterone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000359	0.00198	CcSEcCtD
Abiraterone—Urethral disorder—Epirubicin—thyroid cancer	0.000358	0.00198	CcSEcCtD
Abiraterone—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000347	0.0185	CbGpPWpGaD
Abiraterone—Cardiac disorder—Epirubicin—thyroid cancer	0.000339	0.00187	CcSEcCtD
Abiraterone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000334	0.00184	CcSEcCtD
Abiraterone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000332	0.00183	CcSEcCtD
Abiraterone—Angiopathy—Epirubicin—thyroid cancer	0.000331	0.00183	CcSEcCtD
Abiraterone—Urethral disorder—Doxorubicin—thyroid cancer	0.000331	0.00183	CcSEcCtD
Abiraterone—Mediastinal disorder—Epirubicin—thyroid cancer	0.000329	0.00182	CcSEcCtD
Abiraterone—Arrhythmia—Epirubicin—thyroid cancer	0.000326	0.0018	CcSEcCtD
Abiraterone—Mental disorder—Epirubicin—thyroid cancer	0.00032	0.00177	CcSEcCtD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000318	0.017	CbGpPWpGaD
Abiraterone—Cardiac disorder—Doxorubicin—thyroid cancer	0.000314	0.00173	CcSEcCtD
Abiraterone—Angiopathy—Doxorubicin—thyroid cancer	0.000307	0.00169	CcSEcCtD
Abiraterone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000305	0.00168	CcSEcCtD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—BRAF—thyroid cancer	0.000303	0.0162	CbGpPWpGaD
Abiraterone—Arrhythmia—Doxorubicin—thyroid cancer	0.000302	0.00167	CcSEcCtD
Abiraterone—SULT2A1—Biological oxidations—RXRA—thyroid cancer	0.000299	0.0159	CbGpPWpGaD
Abiraterone—CYP17A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000299	0.0159	CbGpPWpGaD
Abiraterone—Mental disorder—Doxorubicin—thyroid cancer	0.000296	0.00163	CcSEcCtD
Abiraterone—Anaemia—Epirubicin—thyroid cancer	0.000294	0.00162	CcSEcCtD
Abiraterone—SULT2A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000288	0.0154	CbGpPWpGaD
Abiraterone—Cough—Epirubicin—thyroid cancer	0.000277	0.00153	CcSEcCtD
Abiraterone—ABCC1—S1P1 pathway—PTGS2—thyroid cancer	0.000277	0.0148	CbGpPWpGaD
Abiraterone—Hypertension—Epirubicin—thyroid cancer	0.000275	0.00151	CcSEcCtD
Abiraterone—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000273	0.0146	CbGpPWpGaD
Abiraterone—Anaemia—Doxorubicin—thyroid cancer	0.000272	0.0015	CcSEcCtD
Abiraterone—Myalgia—Epirubicin—thyroid cancer	0.000271	0.00149	CcSEcCtD
Abiraterone—Chest pain—Epirubicin—thyroid cancer	0.000271	0.00149	CcSEcCtD
Abiraterone—SULT2A1—PPARA activates gene expression—PPARG—thyroid cancer	0.00027	0.0144	CbGpPWpGaD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000269	0.00148	CcSEcCtD
Abiraterone—Discomfort—Epirubicin—thyroid cancer	0.000267	0.00148	CcSEcCtD
Abiraterone—SULT2A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000264	0.0141	CbGpPWpGaD
Abiraterone—Oedema—Epirubicin—thyroid cancer	0.00026	0.00143	CcSEcCtD
Abiraterone—Infection—Epirubicin—thyroid cancer	0.000258	0.00142	CcSEcCtD
Abiraterone—Cough—Doxorubicin—thyroid cancer	0.000257	0.00142	CcSEcCtD
Abiraterone—Hypertension—Doxorubicin—thyroid cancer	0.000254	0.0014	CcSEcCtD
Abiraterone—Skin disorder—Epirubicin—thyroid cancer	0.000252	0.00139	CcSEcCtD
Abiraterone—Chest pain—Doxorubicin—thyroid cancer	0.000251	0.00138	CcSEcCtD
Abiraterone—Myalgia—Doxorubicin—thyroid cancer	0.000251	0.00138	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000249	0.00137	CcSEcCtD
Abiraterone—Discomfort—Doxorubicin—thyroid cancer	0.000248	0.00137	CcSEcCtD
Abiraterone—Oedema—Doxorubicin—thyroid cancer	0.00024	0.00132	CcSEcCtD
Abiraterone—Infection—Doxorubicin—thyroid cancer	0.000239	0.00132	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000236	0.0013	CcSEcCtD
Abiraterone—Insomnia—Epirubicin—thyroid cancer	0.000235	0.00129	CcSEcCtD
Abiraterone—Skin disorder—Doxorubicin—thyroid cancer	0.000233	0.00129	CcSEcCtD
Abiraterone—Dyspnoea—Epirubicin—thyroid cancer	0.000231	0.00128	CcSEcCtD
Abiraterone—Dyspepsia—Epirubicin—thyroid cancer	0.000228	0.00126	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000224	0.00124	CcSEcCtD
Abiraterone—Fatigue—Epirubicin—thyroid cancer	0.000224	0.00123	CcSEcCtD
Abiraterone—Constipation—Epirubicin—thyroid cancer	0.000222	0.00122	CcSEcCtD
Abiraterone—SULT2A1—Metabolism—MINPP1—thyroid cancer	0.00022	0.0117	CbGpPWpGaD
Abiraterone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000219	0.00121	CcSEcCtD
Abiraterone—Insomnia—Doxorubicin—thyroid cancer	0.000217	0.0012	CcSEcCtD
Abiraterone—Dyspnoea—Doxorubicin—thyroid cancer	0.000214	0.00118	CcSEcCtD
Abiraterone—Dyspepsia—Doxorubicin—thyroid cancer	0.000211	0.00117	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000207	0.00114	CcSEcCtD
Abiraterone—Fatigue—Doxorubicin—thyroid cancer	0.000207	0.00114	CcSEcCtD
Abiraterone—Constipation—Doxorubicin—thyroid cancer	0.000205	0.00113	CcSEcCtD
Abiraterone—Body temperature increased—Epirubicin—thyroid cancer	0.000205	0.00113	CcSEcCtD
Abiraterone—Body temperature increased—Doxorubicin—thyroid cancer	0.00019	0.00105	CcSEcCtD
Abiraterone—SULT2A1—Metabolism—NDUFA13—thyroid cancer	0.000187	0.00996	CbGpPWpGaD
Abiraterone—Asthenia—Epirubicin—thyroid cancer	0.000186	0.00103	CcSEcCtD
Abiraterone—SULT2A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000182	0.00971	CbGpPWpGaD
Abiraterone—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000182	0.00969	CbGpPWpGaD
Abiraterone—Diarrhoea—Epirubicin—thyroid cancer	0.000178	0.00098	CcSEcCtD
Abiraterone—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000177	0.00944	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—CHST14—thyroid cancer	0.000176	0.00937	CbGpPWpGaD
Abiraterone—Asthenia—Doxorubicin—thyroid cancer	0.000172	0.00095	CcSEcCtD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000169	0.009	CbGpPWpGaD
Abiraterone—Vomiting—Epirubicin—thyroid cancer	0.000165	0.00091	CcSEcCtD
Abiraterone—Diarrhoea—Doxorubicin—thyroid cancer	0.000164	0.000906	CcSEcCtD
Abiraterone—Rash—Epirubicin—thyroid cancer	0.000164	0.000903	CcSEcCtD
Abiraterone—Dermatitis—Epirubicin—thyroid cancer	0.000163	0.000902	CcSEcCtD
Abiraterone—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000163	0.00872	CbGpPWpGaD
Abiraterone—CYP17A1—Biological oxidations—RXRA—thyroid cancer	0.000159	0.00846	CbGpPWpGaD
Abiraterone—Vomiting—Doxorubicin—thyroid cancer	0.000153	0.000842	CcSEcCtD
Abiraterone—Rash—Doxorubicin—thyroid cancer	0.000151	0.000835	CcSEcCtD
Abiraterone—Dermatitis—Doxorubicin—thyroid cancer	0.000151	0.000834	CcSEcCtD
Abiraterone—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000145	0.00775	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—HPGD—thyroid cancer	0.000142	0.00755	CbGpPWpGaD
Abiraterone—ABCC1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000128	0.00681	CbGpPWpGaD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—AKT1—thyroid cancer	0.000123	0.00657	CbGpPWpGaD
Abiraterone—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000121	0.00647	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—MINPP1—thyroid cancer	0.000117	0.00622	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000115	0.00612	CbGpPWpGaD
Abiraterone—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000108	0.00575	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000102	0.00543	CbGpPWpGaD
Abiraterone—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	9.96e-05	0.00532	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—NDUFA13—thyroid cancer	9.91e-05	0.00529	CbGpPWpGaD
Abiraterone—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.84e-05	0.00525	CbGpPWpGaD
Abiraterone—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	9.5e-05	0.00507	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—CHST14—thyroid cancer	9.32e-05	0.00497	CbGpPWpGaD
Abiraterone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	8.2e-05	0.00437	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—TPR—thyroid cancer	8.13e-05	0.00434	CbGpPWpGaD
Abiraterone—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	8.08e-05	0.00431	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PRKAR1A—thyroid cancer	8e-05	0.00427	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—HPGD—thyroid cancer	7.51e-05	0.00401	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.25e-05	0.00387	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TRIM24—thyroid cancer	7.14e-05	0.00381	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—MINPP1—thyroid cancer	7.03e-05	0.00375	CbGpPWpGaD
Abiraterone—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	6.98e-05	0.00372	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CHST14—thyroid cancer	6.71e-05	0.00358	CbGpPWpGaD
Abiraterone—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	6.51e-05	0.00348	CbGpPWpGaD
Abiraterone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	6.48e-05	0.00346	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TRIM33—thyroid cancer	6.36e-05	0.00339	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.09e-05	0.00325	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—SLC5A5—thyroid cancer	6.09e-05	0.00325	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—NDUFA13—thyroid cancer	5.98e-05	0.00319	CbGpPWpGaD
Abiraterone—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	5.94e-05	0.00317	CbGpPWpGaD
Abiraterone—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	5.94e-05	0.00317	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.7e-05	0.00304	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CHST14—thyroid cancer	5.62e-05	0.003	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—TPR—thyroid cancer	5.56e-05	0.00296	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—CP—thyroid cancer	5.56e-05	0.00296	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.56e-05	0.00296	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.52e-05	0.00295	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.47e-05	0.00292	CbGpPWpGaD
Abiraterone—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.28e-05	0.00282	CbGpPWpGaD
Abiraterone—CYP2C8—Biological oxidations—RXRA—thyroid cancer	5.23e-05	0.00279	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—RXRA—thyroid cancer	5.11e-05	0.00273	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.97e-05	0.00265	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—HPGD—thyroid cancer	4.53e-05	0.00242	CbGpPWpGaD
Abiraterone—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	4.44e-05	0.00237	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	4.41e-05	0.00235	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—TPR—thyroid cancer	4.31e-05	0.0023	CbGpPWpGaD
Abiraterone—CYP2D6—Biological oxidations—RXRA—thyroid cancer	4.29e-05	0.00229	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TCF7L1—thyroid cancer	4.25e-05	0.00226	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PRKAR1A—thyroid cancer	4.24e-05	0.00226	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.16e-05	0.00222	CbGpPWpGaD
Abiraterone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	3.86e-05	0.00206	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.85e-05	0.00205	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—MINPP1—thyroid cancer	3.84e-05	0.00205	CbGpPWpGaD
Abiraterone—ALB—Metabolism—MINPP1—thyroid cancer	3.82e-05	0.00204	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.68e-05	0.00196	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.49e-05	0.00186	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—PRKAR1A—thyroid cancer	3.43e-05	0.00183	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—TP53—thyroid cancer	3.31e-05	0.00176	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NDUFA13—thyroid cancer	3.26e-05	0.00174	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NDUFA13—thyroid cancer	3.25e-05	0.00173	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—SLC5A5—thyroid cancer	3.23e-05	0.00172	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PPARG—thyroid cancer	3.23e-05	0.00172	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—MINPP1—thyroid cancer	3.15e-05	0.00168	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TPR—thyroid cancer	3.11e-05	0.00166	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CHST14—thyroid cancer	3.07e-05	0.00164	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PRKAR1A—thyroid cancer	3.06e-05	0.00163	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CHST14—thyroid cancer	3.05e-05	0.00163	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.03e-05	0.00161	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	3.02e-05	0.00161	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	3.02e-05	0.00161	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.97e-05	0.00158	CbGpPWpGaD
Abiraterone—ABCC1—Disease—MEN1—thyroid cancer	2.92e-05	0.00156	CbGpPWpGaD
Abiraterone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	2.81e-05	0.0015	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—RXRA—thyroid cancer	2.71e-05	0.00145	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NDUFA13—thyroid cancer	2.68e-05	0.00143	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.64e-05	0.00141	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—TPR—thyroid cancer	2.6e-05	0.00139	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PRKAR1A—thyroid cancer	2.56e-05	0.00137	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PTGS2—thyroid cancer	2.54e-05	0.00135	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CHST14—thyroid cancer	2.52e-05	0.00134	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—HPGD—thyroid cancer	2.47e-05	0.00132	CbGpPWpGaD
Abiraterone—ALB—Metabolism—HPGD—thyroid cancer	2.46e-05	0.00131	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CALCA—thyroid cancer	2.33e-05	0.00124	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.32e-05	0.00124	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—IFNA2—thyroid cancer	2.27e-05	0.00121	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.26e-05	0.0012	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PTEN—thyroid cancer	2.22e-05	0.00118	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CDK1—thyroid cancer	2.11e-05	0.00112	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.06e-05	0.0011	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—HPGD—thyroid cancer	2.03e-05	0.00108	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.01e-05	0.00107	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2e-05	0.00106	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—SLC5A5—thyroid cancer	1.95e-05	0.00104	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.9e-05	0.00101	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.83e-05	0.000974	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.75e-05	0.000935	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PPARG—thyroid cancer	1.71e-05	0.000914	CbGpPWpGaD
Abiraterone—ABCC1—Disease—NRG1—thyroid cancer	1.69e-05	0.000902	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CHST14—thyroid cancer	1.65e-05	0.000879	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—RXRA—thyroid cancer	1.64e-05	0.000873	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.59e-05	0.000849	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TERT—thyroid cancer	1.52e-05	0.00081	CbGpPWpGaD
Abiraterone—ABCC1—Disease—HIF1A—thyroid cancer	1.45e-05	0.000774	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—TPR—thyroid cancer	1.42e-05	0.000758	CbGpPWpGaD
Abiraterone—ALB—Metabolism—TPR—thyroid cancer	1.41e-05	0.000754	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	1.4e-05	0.000746	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PRKAR1A—thyroid cancer	1.39e-05	0.000742	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PTGS2—thyroid cancer	1.35e-05	0.000719	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—HPGD—thyroid cancer	1.33e-05	0.000708	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—AKT1—thyroid cancer	1.28e-05	0.000681	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.27e-05	0.000676	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.26e-05	0.000672	CbGpPWpGaD
Abiraterone—ABCC1—Disease—BRAF—thyroid cancer	1.2e-05	0.000641	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PTEN—thyroid cancer	1.18e-05	0.000627	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—TPR—thyroid cancer	1.17e-05	0.000622	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.15e-05	0.000612	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.06e-05	0.000567	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.06e-05	0.000566	CbGpPWpGaD
Abiraterone—ALB—Metabolism—SLC5A5—thyroid cancer	1.06e-05	0.000564	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PPARG—thyroid cancer	1.03e-05	0.000551	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.97e-06	0.000532	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.91e-06	0.000529	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PTGS2—thyroid cancer	9.71e-06	0.000518	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—RXRA—thyroid cancer	8.94e-06	0.000477	CbGpPWpGaD
Abiraterone—ALB—Metabolism—RXRA—thyroid cancer	8.89e-06	0.000474	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—SLC5A5—thyroid cancer	8.73e-06	0.000466	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.69e-06	0.000464	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.64e-06	0.000461	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—NRAS—thyroid cancer	8.47e-06	0.000452	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PTEN—thyroid cancer	8.47e-06	0.000452	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PTGS2—thyroid cancer	8.13e-06	0.000434	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—TPR—thyroid cancer	7.63e-06	0.000407	CbGpPWpGaD
Abiraterone—ABCC1—Disease—NRAS—thyroid cancer	7.55e-06	0.000403	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	7.5e-06	0.0004	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—RXRA—thyroid cancer	7.34e-06	0.000391	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—KRAS—thyroid cancer	7.29e-06	0.000389	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PTEN—thyroid cancer	7.09e-06	0.000378	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—AKT1—thyroid cancer	6.77e-06	0.000361	CbGpPWpGaD
Abiraterone—ABCC1—Disease—KRAS—thyroid cancer	6.5e-06	0.000347	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—TP53—thyroid cancer	6.48e-06	0.000346	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—HRAS—thyroid cancer	6.2e-06	0.000331	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	5.71e-06	0.000305	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PPARG—thyroid cancer	5.64e-06	0.000301	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PPARG—thyroid cancer	5.61e-06	0.000299	CbGpPWpGaD
Abiraterone—ABCC1—Disease—HRAS—thyroid cancer	5.53e-06	0.000295	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—AKT1—thyroid cancer	5.47e-06	0.000292	CbGpPWpGaD
Abiraterone—ABCC1—Disease—AKT1—thyroid cancer	4.88e-06	0.00026	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—RXRA—thyroid cancer	4.8e-06	0.000256	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PPARG—thyroid cancer	4.63e-06	0.000247	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PTGS2—thyroid cancer	4.44e-06	0.000237	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PTGS2—thyroid cancer	4.41e-06	0.000235	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—AKT1—thyroid cancer	4.09e-06	0.000218	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PTEN—thyroid cancer	3.87e-06	0.000207	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PTEN—thyroid cancer	3.85e-06	0.000205	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PTGS2—thyroid cancer	3.64e-06	0.000194	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PTEN—thyroid cancer	3.18e-06	0.00017	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PPARG—thyroid cancer	3.03e-06	0.000162	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.38e-06	0.000127	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—AKT1—thyroid cancer	2.23e-06	0.000119	CbGpPWpGaD
Abiraterone—ALB—Metabolism—AKT1—thyroid cancer	2.22e-06	0.000118	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PTEN—thyroid cancer	2.08e-06	0.000111	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—AKT1—thyroid cancer	1.83e-06	9.77e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—AKT1—thyroid cancer	1.2e-06	6.39e-05	CbGpPWpGaD
